Massimo Casi, MD

Recordati SpA
Milan, Italy

Disclosure information not submitted.

Presentation(s):

• MON-015 - Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients with Hypertension Caused by Cushing'S Syndrome with Mean Urinary Free Cortisol ≤2X the Upper Limit of Normal: LINC CARE Study Design

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT